Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/26/2025 | $20.00 | Buy | B. Riley Securities |
| 4/22/2025 | $21.00 | Buy | Craig Hallum |
| 3/17/2025 | $20.00 | Buy | H.C. Wainwright |
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
B. Riley Securities initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00
Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00
H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through key anticipated regulatory inflection pointsAdditional nonclinical studies are ongoing combining elraglusib with RAS inhibitors based on potential synergies and complimentary mechanisms of action CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price, before underwriting discounts and commissions, for each share of com
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten public offering of 2,142,858 shares of its common stock at an offering price of $7.00 per share of common stock. Actuate has granted the underwriters a 30-day option to purchase up to 321,428 additional shares of its common stock sold in the offering at the public offering price per share, less underwriti
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)